Skip to main content

Link Between Inflammatory Disease, Adverse Pregnancy Outcomes Varies

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 12, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Feb. 12, 2024 -- The association between immune-mediated inflammatory diseases (IMIDs) and adverse pregnancy outcomes varies with the nature of IMID and the presence of comorbidities, according to a study published online Feb. 1 in eClinicalMedicine.

Yeon Mi Hwang, from the Institute for Systems Biology in Seattle, and colleagues conducted a retrospective cohort study to examine the impact of 12 selected IMIDs on adverse pregnancy outcomes. The analytic cohort included 365,075 people: 5,784 in the IMID group and 359,291 in the non-IMID group.

The researchers found that in the previous 10 years, the prevalence rate of pregnancy of at least 20 weeks duration doubled in people with a previous IMID diagnosis. Of the IMID group, 17 percent had at least one prenatal immunomodulatory medication (IMM) prescription; 48 to 70 percent of the patients taking IMMs before pregnancy continued them throughout pregnancy, depending on the type of IMM. Compared with a matched cohort of people without IMIDs, patients with one or more of the 12 IMIDs had an increased risk for preterm birth (PTB), low birth weight (LBW), small for gestational age, and cesarean section overall (relative risks [95 percent confidence intervals], 1.1 [1.0 to 1.3], 1.2 [1.0 to 1.4], 1.1 [1.0 to 1.2], and 1.1 [1.1 to 1.2], respectively). Risk was not significantly increased for PTB or LBW among patients with rheumatoid arthritis and/or inflammatory bowel disease, after adjustment for comorbidities.

"Each type of autoimmune disease is different, each person has their own medical history, and risk may change throughout pregnancy," lead author Jennifer Hadlock, M.D., also from the Institute for Systems Biology, said in a statement. "This study highlights the importance of taking comorbidities into consideration."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

American College of Obstetricians and Gynecologists, May 17-19

The annual meeting of the American College of Obstetricians and Gynecologists was held from May 17 to 19 in San Francisco and was attended by more than 4,000 clinicians...

Epidural Analgesia Linked to Decline in Severe Maternal Morbidity

FRIDAY, May 24, 2024 -- Epidural analgesia during labor is associated with a reduction in severe maternal morbidity (SMM), according to a study published online May 22 in The...

Prenatal Exposure to Endocrine-Disrupting Chemicals Affects Child's Metabolic Health

FRIDAY, May 24, 2024 -- Prenatal exposure to endocrine-disrupting chemicals (EDCs) is associated with adverse metabolic health in children, according to a study published online...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.